ATE546148T1 - Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung - Google Patents

Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung

Info

Publication number
ATE546148T1
ATE546148T1 AT06761149T AT06761149T ATE546148T1 AT E546148 T1 ATE546148 T1 AT E546148T1 AT 06761149 T AT06761149 T AT 06761149T AT 06761149 T AT06761149 T AT 06761149T AT E546148 T1 ATE546148 T1 AT E546148T1
Authority
AT
Austria
Prior art keywords
combination
fluoropyrimidines
cancer treatment
chlorite solutions
fluoropyrimidine
Prior art date
Application number
AT06761149T
Other languages
English (en)
Inventor
Stefan Meuer
Thomas Giese
Friedrich Wilhelm Kuhne
Original Assignee
Nuvo Res Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Res Ag filed Critical Nuvo Res Ag
Application granted granted Critical
Publication of ATE546148T1 publication Critical patent/ATE546148T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT06761149T 2005-07-21 2006-07-21 Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung ATE546148T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70107505P 2005-07-21 2005-07-21
PCT/CA2006/001187 WO2007009245A1 (en) 2005-07-21 2006-07-21 Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.

Publications (1)

Publication Number Publication Date
ATE546148T1 true ATE546148T1 (de) 2012-03-15

Family

ID=37668401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06761149T ATE546148T1 (de) 2005-07-21 2006-07-21 Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung

Country Status (8)

Country Link
US (2) US20080292729A1 (de)
EP (2) EP2428213A1 (de)
JP (2) JP2009501734A (de)
AT (1) ATE546148T1 (de)
AU (1) AU2006272343B2 (de)
CA (1) CA2616008A1 (de)
ES (1) ES2384267T3 (de)
WO (1) WO2007009245A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
EP1937286B1 (de) 2005-09-12 2016-03-09 Abela Pharmaceuticals, Inc. Zusammensetzungen aus dimethylsulfoxid (dmso)
EP1966229B1 (de) 2005-09-12 2015-10-21 Abela Pharmaceuticals, Inc. Systeme zur entfernung von dimethylsulfoxid (dmso) oder verwandten verbindungen, oder damit assoziierten gerüchen
CA2779111C (en) 2009-10-30 2019-08-13 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
CA2807723A1 (en) * 2010-08-13 2012-02-16 Servet Buyuktimkin Foamable compositions of stabilized chlorite
WO2013093891A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
WO2014037927A1 (en) 2012-09-10 2014-03-13 Nuvo Research Gmbh Chlorate compositions and use of chlorate for treating radiation exposure
IL299751A (en) 2020-07-07 2023-03-01 Wiab Water Innovation Ab Preparations and methods for disinfection, treatment and prevention of bacterial infections
WO2023021329A1 (en) 2021-08-17 2023-02-23 Wiab Water Innovation Ab Compositions and methods to disinfect, treat and prevent microbial infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3515748A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer isotonen chloritmatrix-loesung bei der behandlung von tumoren
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
EP1408994A2 (de) * 1999-08-18 2004-04-21 OXO Chemie AG Chemische-stabilizierte chlorit lösungen für das behandeln des krebses
EP1622624B1 (de) * 2003-05-08 2007-12-26 Eisai R&D Management Co., Ltd. Medizinische zusammensetzungen enthaltend n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzensulfonamid und weitere cytostatika
UA101945C2 (uk) * 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
RU2006106267A (ru) * 2003-08-01 2006-07-27 Уайт Холдингз Корпорейшн (Us) Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
PT1689404E (pt) * 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro

Also Published As

Publication number Publication date
WO2007009245A1 (en) 2007-01-25
EP1906977A1 (de) 2008-04-09
US20080292729A1 (en) 2008-11-27
EP1906977A4 (de) 2008-09-03
JP2013173745A (ja) 2013-09-05
AU2006272343A1 (en) 2007-01-25
CA2616008A1 (en) 2007-01-25
EP2428213A1 (de) 2012-03-14
US20130202719A1 (en) 2013-08-08
JP2009501734A (ja) 2009-01-22
EP1906977B1 (de) 2012-02-22
AU2006272343B2 (en) 2012-09-13
ES2384267T3 (es) 2012-07-03

Similar Documents

Publication Publication Date Title
ATE546148T1 (de) Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
GEP20237560B (en) Fused pyrazine derivatives as a2a / a2b inhibitors
TN2010000040A1 (en) 2-3-7-substituted imidazo - [1-2b] pyridazines for treatment of alk 4 or alk 5 mediated diseases
DK1450799T5 (da) Arulurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
ATE521608T1 (de) Glucokinaseaktivatoren
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
MY148985A (en) 2-aminopyridine analogs as glucokinase activators
TW200740804A (en) Glucokinase activators
IL180137A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
CY1112281T1 (el) Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη
MX2018003186A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer.
IL180138A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer
HK1155664A1 (en) Treatment of metastasized tumors
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
WO2016201365A3 (en) Methods for treating cancers
CL2009001159A1 (es) Difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6{[1-(n-metilcarbamoilmetil)piperidin-4-il]oxi]quinazolina; forma cristalina a del difumarato; procesos de preparacion; composicion faramceutica; y uso para tratar cancer de mama, gastrico, colorrectal, de cabeza y cuello, de ovario y de pulmon.
GB2460976B (en) Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
CL2008000231A1 (es) Forma solida de (8e,12e,14e)-7-((4-cicloheptilpiperazin-1-il)carbonil)oxi-3,6,16,21-tetrahidroxi-6,10,12,16,20-pentametil-18,19-epoxitricosa-8,12,14-trien-il-olido; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
ATE427363T1 (de) In kanzerísen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
MX2023006434A (es) Inhibidores de quinasa y usos de los mismos.
WO2019126136A3 (en) Pyrimidine compounds useful as tyrosine kinase inhibitors
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.